LTL-305 datasheet

Origin	Primary human ovarian cancer	**Histopathology**	Clear cell carcinoma
Year of establishment	2008	**Doubling time**	Not determined (early generation)
Local invasion	No	**Metastasis**	No
Drug sensitivity	Not determined		

The LTL-305 was developed from a patient's primary ovarian cancer (ovarian clear cell carcinoma). Histopathologically, it closely resembles the patient's tumor (Figs 1, 2). When grafted under the renal capsules of SCID mice, the LTL-305 shows no local invasion into adjacent host kidney parenchyma. No metastasis was observed.



Fig. 1. H&E stained LTL-305 tissue sections.

LTL-305 tissue grown under the renal capsules of SCID mice, showing a clear cell carcinoma, closely resembling the histopathology of original patient's cancer, as shown in Figure 2. (x400)



Fig. 2. Patient's cancer tissue before grafting.

The tumor is a clear cell carcinoma. The tumor cells have clear cytoplasm and distinct cytomembrane.

Genetic and epigenetic characteristics

Tissue microarrays containing LTL-305 tissue are available for screening potential molecular targets.

Applications

1. Pre-clinical evaluation of existing and potential anticancer drugs. Examination of drug efficacy on tumor growth, cell death (apoptosis, necrosis) and angiogenesis.

2. Discovery of potential therapeutic targets and/or biomarkers for drug sensitivity.

3. Study of mechanisms underlying tumor growth and progression.

References

1. Lee et al., Gynecologic Oncology 2005; 96: 48-71

2. Press et al., Gynecologic Oncology 2008; 110: 256-280

For more information, please contact us by email: LTL@bccrc.ca or phone: (604) 675 8013